Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
|
Your cart is empty |
|||
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
Nuclear Oncogenes as Transcription Factors.- Control of Hepatocyte Growth by Positive and Negative Growth Regulators and Mitogenic Triggers: Implications for Hepatic Neoplasia.- Cell Cycle Dependent Regulation of Poly(ADP-Ribose) Polymerase Gene Expression.- Different Expression of Cell Cycle Related Genes During Liver Regeneration and Liver Hyperplasia.- S-Adenosylmethionine Content, DNA Methylation and Gene Expression in Regenerating Liver.- Gene Activation and Deactivation During Multistage Hepatocarcinogenesis in the Rat.- Biochemical and Molecular Perturbations Induced in Preneoplastic Tissue by a S-Adenosyl-L-Methionine Load.- Alterations of Cell Surface Receptors and Expression of Cellular Oncogenes in the Liver of Rats Fed a Hypolipidemic Peroxisome Proliferator.- Growth Hormone-Regulated Expression of c-myc Gene During sex-Differentiated Promotion of Rat Liver Carcinogenesis.- In Situ Hybridization of Ha-Ras During Rat Liver Carcinogenesis.- Mutations in the H-Ras Proto-Oncogene in Early Precancerous Liver Lesions of the B6C3F1 Mouse.- Transformation of Human Epithelial Cells by Recombinant Human Papillomavirus DNA Associated with Cervical Cancer.- Cancer Families and Susceptibility to Cancer.- Cancer Syndromes in Humans.- Case-Control Studies on Cancer Risk in G6PD-Deficient Male Populations.- Genetic Susceptibility to Murine Hepatocarcinogenesis.- MHC-Linked Genes Controlling Growth and Reproduction Influence the Susceptibility to Diethylnitrosamine-Induced Carcinogenesis.- Metabolic Aberrations and Metamorphosis During Chemical Carcinogenesis.- Persistent Rat Liver Nodules Differ from Normal Liver, Regenerating Liver and Early Nodules both in Terms of Proteins of the Nuclear Matrix and Chromatin Condensation.- Intracellular Na+, K+, H+ and Cl? Activities and Membrane Potentials During the 4-Dimethylaminoazobenzene-Induced Rat Hepatocarcinogenesis.- Analysis of the Effects of Modifying Agents on Proliferation and Enzyme Phenotype in Focal Preneoplastic and Neoplastic Liver Lesions in Rats.- Epidermal Growth Factor-Induced Cell Proliferation and EGF Binding in Preneoplastic Foci in The Rat Liver.- The Different Calcium Requirements of the Mitogenic Effects Elicited in Primary Neonatal Rat Hapatocytes by the Diterpene Phorbol Esters 12-O-Tetradecanoylphorbol-13-Acetate and Sapintoxin A.- Glucose-6-Phosphate Dehydrogenase Molecular Forms in Different Experimental Models of Hepatic Cell Proliferation.- Estrogen Dependent Growth of a Rat Pituitary Tumor (MtT/F84).- Deterministic Coupling Between Cellular Bioenergetics, Cholesterol Synthesis, cell Proliferation and Cancer.- Dolichyl Phosphate as a Regulator of Cell Growth.- Regulation of Cholesterol Metabolism in Normal and Malignantly Transformed Tissue in Vivo.- Cholesterol Metabolism and Proliferative Processes.- Serum LCAT and Lipid Levels in grc-- Bearing Rats with Liver Cancer.- Covalent Modification of Proteins by Farnesol and the Control of Cell Proliferation.- Repeated Treatments with a Low HNE Concentration Affect K562 Cell Proliferation.- Arachidonic Acid Enrichment Augments the Malonildialdehyde Production in Yoshida AH-130 Hepatoma Cells.- Modulation of Phosphatidylinositol-4,5-Diphosphate (PIP2)-Phospholipase C Activity by 4-Hydroxyalkenals.- The Role of Hepatic Metabolism in Sex Differentiation of Chemical Hepatocarcinogenesis in the Rat.- Changes of Rat Liver Glutathione Peroxidase, Glutathione Reductase and Glutathione Transferase 7-7 by Lead Nitrate Treatment.- High Affinity P-450 Form for the Metabolic Activation of DEN in Liver of Acetone-Induced Rats but not of Hamsters.- Genotoxicity of Chloroethanes and Structure Activity Relationships.- Genetical and Biochemical Studies on Three Halogenated Ethanes.- "In Vivo" Interaction of Methionine and Cysteine Sulfur with Rat Liver tRNA.- Synthesis and Secretion of Cathepsin D in Normal And Tumor Human Cells.- Relationship Between Cell Proliferation and Cell Death.- An in Vitro Model for Apoptosis: Uptake a...
This book reviews recent knowledge of the role of gut microbiome in health and disease. It covers extensive topics for several diseases, including metabolic-related diseases, allergies, gastrointestinal diseases, psychiatric diseases, and cancer, while also discussing therapeutic approaches by microbiota modification. Comprehensive and cutting-edge, Gut Microbiome-Related Diseases and Therapies deepens a reader's theoretical expertise in gut microbiome. Graduate and postdoctoral students, medical doctors, and biomedical researchers will benefit from this book.
Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
Fluoropyrimidine Metabolism and Mechanism of Action.- 5-Fluoro-2?-Deoxyuridine: Role of Schedule in its Therapeutic Efficacy.- Comparison of Continuous Infusions and Bolus Injections of 5- Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase.- Critical Questions for the Future Direction of FU/LV.- Cellular Interactions Between the Natural and Unnatural Isomers of 5-Formyltetrahydrofolate.- Leucovorin as a Prodrug.- Clinical Use of Leucovorin: Intracellular Metabolism.- Some Considerations Concerning the Dose and Schedule of 5FU and Leucovorin: Toxicities of Two Dose Schedules from the Intergroup Colon Adjuvant Trial (INT-0089).- Effects of 5-Fluorouracil on mRNA.- Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine.- Experience with 5FU + L-Leucovorin.- 5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I-II Study of Two Consecutive Regimens.- 5-Fluorouracil Modulation in Colorectal Carcinoma: Experience of German Investigators.- An Overview of Adjuvant Treatment of Colon Cancer.- Dose-Dependent Inhibition of Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear Cells in Patients Receiving N-Phosphonacetyl)-L-Aspartate.- Alternative Approaches to Modulation of Fluoropyrimidines.- Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies.- Enchanced Cytotoxicity of 5-Fluorouracil Combined with [6RS]-Leucovorin and Recombinant Human Interferon-?2a in Colon Carcinoma Cells.- Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma.- Biochemical Modulation of 5-Fluorouracil by PALA: Mechanism of Action.- Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy.- Update on Metabolic Modulation as a Therapeutic Approach for Adult Carcinomas.- Fluorouracil and Leucovorin in Advanced Breast Cancer.- Fluorouracil Modulation in Head and Neck Cancer.- Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe.- Rationale for the Combination Therapy of 5FU and CDDP.- Biochemical Modulation of Fluoropyrimidines: The "Giscad" Studies.- New Drugs.- Clinical Experience with UFT in Japan.- Clinical Studies of the Modulation of Ftorafur.- The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694.- The History of the Development and Clinical Use of CB 3717 and ICI D1694.- New Sites of Intervention in the Development of New Drugs in Solid Tumors.- P53: A Determinant of the Cell Cycle Response to DNA Damage.- Therapeutic Implications of Molecular Genetics.- Concluding Remarks.- Summary.- Abbreviations.- Author Index.
The tumor microenvironment has become a very important and hot topic in cancer research within the past few years. The tumor microenvironment is defined as the normal cells, molecules, and blood vessels that surround and feed a tumor cell. As many scientists have realized, studying the tumor microenvironment has become critical to moving the field forward, since there are many players in a tumor's localized and surrounding area, which can significantly change cancer cell behavior. There is a dual relationship wherein the tumor can change its microenvironment and the microenvironment can affect how a tumor grows and spreads. Tumor Microenvironment in Cancer Progression and Cancer Therapy aims to shed light on the mechanisms, factors, and mediators that are involved in the cancer cell environment. Recent studies have demonstrated that in addition to promoting tumor progression and protecting tumor cells from the spontaneous immune-mediated rejection and different forms of cancer therapeutics, tumor microenvironment can also be a target and mediator of both standard and newly-emerging forms of cancer therapeutics. Thus, the dual role of the tumor microenvironment is the integral focus of the volume. The volume highlights the bi-directional interactions between tumor cells and non-malignant tumor component during tumor progression and treatment. It also focuses on the three groups of the reactive tumor component: stromal cells, blood vessels and the infiltrating immune cells. These three groups are discussed under the lens of their role in promoting tumor growth, shielding the tumor from rejection and from standard forms of cancer therapies. They are emerging as targets and mediators of standard and new forms of potential therapy.
There are more than 63,000 new cases of uterine and endometrial cancer each year in the United States, up from approximately 41,000 when the first edition of Uterine Cancer was published in 2009. A book focusing on these cancers was timely, with emergent sophistication in diagnosis increasingly impacting clinical decision-making. However, five years later, the need for an updated book on this topic is even stronger as oncologists recognize opportunities to impact the outcome on women that are increasingly diagnosed with these malignancies. Uterine Cancer: Screening, Diagnosis, and Treatment, Second Edition, part of the Current Clinical Oncology series, enhances the awareness on this somewhat neglected area of therapeutics, helping to integrate targeted therapies into the management of women with uterine cancer. Written by experts in the field in a highly practical and comprehensive manner, it is a must-have for all gynecological residents and fellows, as well as gynecological oncologists, medical oncologists, radiation oncologists, and family practice doctors who wish to provide their patients with the best possible care.
The study of the molecular events leading to cellular transformation and cancer has progressed significantly in the last decade, and it has become apparent that many genes subject to modification in cancer are, in fact, transcription factors that govern the execution of the genetic programme of the cell. Transcription factors can behave either as oncogenes or as tumour suppressor genes. To date only a limited number of transcription factors have been associated with cancer. This volume deals with several transcription factor families that were first identified in oncogenic retroviruses. Each chapter contains a description of the structure of the transcription factors, the nature of target genes, the regulation of their activities, and an explaination of how they can deregulate cell growth and differentiation. This text should be suitable for the specialist scientist and the advanced student
This book is a compilation of past and recent knowledge in the field of emerging drug resistance. The book covers major aspects of drug resistance in bacteria, fungi, malaria, and cancer.Human survival on earth is constantly threatened by disease and syndrome. From the early days, the aim of research in medicine was to find therapeutic agents that can improve the quality of human life. Although humans are dependent on natural compounds from early days their dependence of drugs increased excessively in last century. The advances in chemistry and biology have helped researchers to identify the drugs that have improved treatment of many diseases. The primary factor for treatment of these diseases is dependent on the efficacy of drugs available. The development of resistance to these drugs is one of the major hindrances. Although there are number of books available on this topic, "drug resistance" biology across kingdoms has never been discussed in a coherent way.
Retinoids have received considerable attention in recent years and due cognizance has been given to their versatility as biological response modifiers, as evidenced by the virtually explosive growth of literature in this field in the past few years. This volume has been designed to give a current state-of-the-art picture of retinoids. The perceived potential of retinoids in the treatment of certain disease stated has initiated attempts at identifying and synthesizing new retinoid derivatives with definable and selective effects on aberrant biological phenomena. Appropriately, therefore, we begin with the chemistry of retinoids and their derivatives together with discussions of their biological activity. Major advances have been made in understanding the mechanisms by which retinoids modulate physiological and phenotypic traits of cells. The transduction of retinoid signaling by the mediation of nuclear receptors of the steroid/thyroid receptor superfamily has now been studied extensively and the cloning and defining the characteristics of these receptors has been a focus of discussion in this volume. Retinoids also markedly modulate the transduction of extracellular signals such as those imparted by growth factors and hormones, and thus actively influence and control cellular proliferative patterns. Retinoids can alter epidermal growth factor receptor expression (Kawaguchi et al., 1994), responsiveness to thyroid hormone (Esfandiari et al., 1994; Pallet et al., 1994), inhibit the proliferative responses of hematopoietic progenitor cells to granulocyte colony stimulating factor (Smeland et al., 1994), and modulate secretion on interleukins by leukaemic cells (Balitrand et al., 1994), among other things. This has obvious implications for pharmacological manipulation of deregulated growth (Dickens and Colletta, 1993; Mulshine et al., 1993). Apoptosis is another component in the regulation of growth control. Apoptotic cell death is influenced by several agents and retinoids may function by interfering with apoptotic pathways of regulation of growth control and quite legitimately, therefore, the importance of this aspect of retinoid function has been duly recognized here.
This book describes in detail current best practice in the diagnosis and treatment of malignant pediatric bone tumors and also discusses other important aspects of management. Clinical assessment, the role of different imaging modalities and choice of biopsy procedure are explained and an individual chapter is devoted to diagnostic pathology. The treatment-oriented chapters offer in-depth descriptions of chemotherapeutic regimens, radiation therapy, limb-salvage options and amputation-related issues and in addition consider the approach to lung nodules, the role of biomarkers, off-therapy monitoring and the treatment of relapse. Psychosocial impacts and needs are addressed and guidance provided on nursing during treatment and rehabilitation following orthopaedic surgery. Closing chapters evaluate emerging therapies and discuss disparate aspects of survivorship. The authors are acknowledged experts and include many contributors from the Nationwide Children's Hospital, a leading pediatric care facility in the United States.
As bone marrow transplant treatments and chemotherapy develop, the population of neutropenic cancer patients is on the rise. These developments are allowing patients to live longer, but in recent years, they have also led to an increase in previously rare infections and syndromes, whose management is unfamiliar to the average healthcare professional. Infections in Neutropenic Cancer Patients is a crucial resource for medical students, residents, practitioners, health professionals, and researchers. It details the clinical presentation, diagnoses, and management of an array of common infections and syndromes specific to neutropenic cancer patients, including real scenarios accompanied by color photos and radiographic results. Chapters include step-by-step tutorials, access to clinical answers on diagnosis and treatment, and a tabulated summary of the key points.
Cancer is a multifaceted and genomically complex disease and data obtained through high throughput technologies has provided near complete resolution of the landscape of how genomic, genetic and epigenetic mutations in cancerous cells effectively influence homeostasis of signaling networks within these cells, between cancerous cells, tumor microenvironment and at the organ level. Increasingly sophisticated information has helped us in developing a better understanding of the underlying mechanisms of cancer, and it is now known that intra-tumor genetic heterogeneity, cellular plasticity, dysregulation of spatio-temporally controlled signaling cascades, and loss of apoptosis are contributory in cancer development, progression and the development of resistance against different therapeutics. It is becoming progressively more understandable that earlier detection of pre-existing or emerging resistance against different therapeutics may prove to be helpful in personalizing the use of targeted cancer therapy. Despite the fact that there is a continuously increasing list of books, being guest edited by researchers, books on the subject are often composed of invited reviews without proper sequence and continuity and designed for a particular readership. This book progressively shifts and guides the readers from basic underlying mechanisms to translational approaches to treat cancer.
This book is a comprehensive understanding of the evolution of pre-malignant disease, emphasizing common themes in the field, including stem cell biology and histologic modes of cancer progression between the distal esophagus and stomach. Its sixteen chapters discuss metaplastic tissue change in the upper GI, clonalexpansion of early neoplasia, stem cell dynamics in experimental models, pathology of early esophageal squamous cell carcinoma, therapeutic modalities for esophageal squamous cell carcinoma, pathology of Barrett's esophagus, screening, early detection and novel diagnostic tools for Barrett's esophagus, clonal evolution of Barrett's esophagus, endoscopic therapeutic modalities of early esophageal cancer, pathology of early gastric cancer, and experimental models for gastric cancer. Stem Cells, Pre-neoplasia and Early Cancer of the Upper Gastrointestinal Tract is an integrative text on both the current state of translational research on every cancer development of the upper gastrointestinal tract as well as on novel clinical diagnostic and therapeutic modalities. It highlights a rapidly growing field within cancer research and is essential reading for oncologists, biochemists and advanced graduate students alike. Springer's Advances in Experimental Medicine and Biology series presents multidisciplinary and dynamic findings in the broad fields of experimental medicine and biology. The wide variety in topics it presents offers readers multiple perspectives on a variety of disciplines including neuroscience, microbiology, immunology, biochemistry, biomedical engineering and cancer research.
This multidisciplinary analysis links epidemiologic, cultural, social, and medical analyses of cancer prevention, detection, and care. The contributors demonstrate that different ethnic groups and cultures have distinct concepts of cancer prevention and control. These ideas are dynamic, shaped by personal and group histories, social networks, technologies, politics, economics, religions, linguistics, and other environmental conditions. Cross-cultural writings about cancer make this book useful to professionals and students in the disciplines of medicine, nursing, public health, sociology, anthropology, and social welfare. The 15 articles reveal that cancer knowledge, attitudes, and behaviors are diverse cross-cultural constructs resulting from distinct experiences. Ideas and behaviors about prevention and control may be shared or individual and idiosyncratic. The book is composed of three sections: I. Cancer Beliefs and Behaviors; II. Interventions in Review; III. New Strategies for Cancer Research. The authors, including anthropologists, epidemiologists, health educators, nurses, and physicians, explicate notions of prevention and control, and assess interventions and methodologies that illustrate generally ignored successes in decreased mortality and morbidity among members of specific populations.
This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and limitations of large-scale production of anti-cancer compounds using biotechnological means. Lastly, it discusses future economical and eco-friendly strategies for obtaining anti-cancer compounds using biotechnology.
This book shares the latest research and practice-oriented findings in medical sciences with a wide audience. It addresses a range of contemporary issues, often unresolved or contentious, across various medical fields, including advances in the management of hemorrhagic brain stroke. It also discusses metastatic renal cell carcinoma - a global scourge with an extremely poor long-term survival prognosis, the course and sequelae of renal cell carcinoma, as well as advances in targeted molecular therapy with sunitinib, a receptor tyrosine kinase inhibitor. Further, it examines the molecular targeting of proliferative signaling of the epidermal growth factor receptor in the first-line treatment of patients with metastatic non-small-cell lung cancer. Other articles cover clearance of toxins in hemodialyzed patients; the search for diagnostic and therapeutic markers in the connective tissue disease scleroderma; obesity linked to inappropriate dietary habit; clinical problems related to the diagnosis of sensitization to fungi and its role in asthma; and reasons for the perilous trend of avoiding basic vaccinations in children. Lastly, the book explores the rapid developments in e-health technologies that increase access to health services, particularly for the elderly. The book is intended for clinical specialists, researchers, and all allied health professionals from various fields.
The Epidemiological Approach to the Study of Protease Inhibitors (Fontham, Correa). In vitro Studies of Anticarcinogenic Protease Inhibitors (Kennedy). Discovery and Background of the BowmanBirk Protease Inhibitors (Bowman). Antigenicity of Soybean Protease Inhibitors (Bandon et al.). Low Molecular Weight Protease Inhibitors of Microbial Origin (Umezawa et al.). Protease Inhibitor Synthesis by MCF7 Breast Cancer Cells (Finlay et al.). Analysis of StructurActivity Relationships of the BowmanBirk Inhibitor of Serine Proteases (Flecker). Prevention of Cancer by Vitamin B3 (Troll). Approaches to Studying the Target Enzymes of Anticarcinogenic Protease Inhibitors (Billings). Anticarcinogenic Activities of Naturally Occuring Cysteine Protease Inhibitors (Colella et al.). Cell Membrane Enzymes Containing ChymotrypsinLike Activity (Yavelow et al.). The Role of Active Oxygen Species in Biological Damage and the Effect of Some Chemopreventative Agents (Frenkel). 6 additional articles. Index.
It has been recognized for almost 200 years that certain families seem to inherit cancer. It is only in the past decade, however, that molecular genetics and epidemiology have combined to define the role of inheritance in cancer more clearly, and to identify some of the genes involved. The causative genes can be tracked through cancer-prone families via genetic linkage and positional cloning. Several of the genes discovered have subsequently been proved to play critical roles in normal growth and development. There are also implications for the families themselves in terms of genetic testing with its attendant dilemmas, if it is not clear that useful action will result. The chapters in this work illustrate what has already been achieved and take a critical look at the future directions of this research and its potential clinical applications.
This invaluable resource discusses insights ranging from basic biological mechanisms of various types of stem cells through the potential applications in the treatment of human diseases, including cancer and genetic disorders. These discoveries are placed within the structural context of tissue and developmental biology in sections dealing with recent advances in understanding different types of stem cell biology and their potential applications in tissue repair and regeneration and in the treatment different types of human cancer and genetic diseases or disorders. Stem Cells for Cancer and Genetic Disease Treatment and the other books in the Stem Cells in Clinical Applicationsseries will be invaluable to scientists, researchers, advanced students and clinicians working in stem cells, regenerative medicine or tissue engineering as well as cancer or genetics research. |
You may like...
Surviving Triple Negative Breast Cancer…
Patricia Prijatel, Carol Scott-Conner
Hardcover
R1,019
Discovery Miles 10 190
|